Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 20/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 20/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 19/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 19/20 | 1.00 |
| ▸ | CHRNG | P07510 | 18/20 | 1.00 |
| ▸ | CHRND | Q07001 | 18/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Radafaxine SCHEMBL30486031 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL29751668 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL29465705 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3453827 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL2599138 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL13014841 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3453734 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL14521595 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL5478077 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3154016 | 1.00 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260027070-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-01-29 | — | — | US | claimed |
| US-20250325510-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APRIMED INC DELAWARE (US) | 2025-10-23 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250186371-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2025-06-12 | — | — | US | claimed |
| US-20250114321-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2025-04-10 | — | — | US | claimed |
| CN-119789855-A | Methods and compositions for treating sleep apnea | 爱普宁公司(特拉华) | 2025-04-08 | — | — | CN | claimed |
| US-20250049803-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-13 | — | — | US | claimed |
| US-20250049779-A1 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-13 | — | — | US | claimed |
| US-20030083330-A1 | Pharmaceutically active morpholinol | SMITHKLINE BEECHAM CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030064988-A1 | Pharmaceutically active morpholinol | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | claimed |
| US-20030032643-A1 | Pharmaceutically active morpholinol | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | claimed |
| WO-2002094323-A1 | WEIGHT REDUCTION OR WEIGHT CONTROLLING COMPOSITION | GLAXO GROUP LIMITED (GB) | 2002-11-28 | — | — | WO | claimed |
| US-20020147196-A1 | Composition and method for treating neuropathic pain | GLAXO GROUP LIMITED (GB) | 2002-10-10 | — | — | US | claimed |
| US-6391875-B2 | Pharmaceutically active morpholinol | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | claimed |
| US-20020019396-A1 | Pharmaceutically active morpholinol | MORGAN PHILLIP FREDERICK (US) | 2002-02-14 | — | — | US | claimed |
| US-6274579-B1 | ANTIDEPRESSANTS, ANALGESICS; SEXUAL DISORDERS, ATTENTION DEFICIT DISORDER; DRUG ADDICTION; PARKINSON*S AND ALZHEIMER*S DISEASE; HEADACHES, OBESITY | GLAXO WELLCOME INC. | 2001-08-14 | — | — | US | claimed |
| EP-1047428-A1 | PHARMACEUTICALLY ACTIVE MORPHOLINOL | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | claimed |
| WO-1999037305-A1 | PHARMACEUTICALLY ACTIVE MORPHOLINOL | GLAXO GROUP LIMITED (GB) | 1999-07-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027070-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | NTSR1, NTSR2, GPR39 | CHRNB2 159/4885SLC6A2 6/4885CHRNB4 81/4885 |
| US-20030032643-A1 | Pharmaceutically active morpholinol | ACHE, MGLL, COMT | CHRNB2 105/4885SLC6A2 119/4885CHRNB4 78/4885 |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | CHRNA2, CHRNA3, ADRA2B | CHRNB2 25/4885SLC6A2 4/4885CHRNB4 35/4885 |
| US-20250114321-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | HCRTR2, CHRM3, CHRM2 | CHRNB2 82/4885SLC6A2 164/4885CHRNB4 75/4885 |
| US-20250049779-A1 | COMBINATION OF AN A2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, ADRA2A | CHRNB2 19/4885SLC6A2 12/4885CHRNB4 43/4885 |
| US-20250325510-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | HCRTR2, CHRM3, CHRM2 | CHRNB2 82/4885SLC6A2 164/4885CHRNB4 75/4885 |
| US-20250049803-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | SLC6A2, SLC6A3, ADRB3 | CHRNB2 77/4885SLC6A2 1/4885CHRNB4 62/4885 |
| US-20030083330-A1 | Pharmaceutically active morpholinol | ACHE, OPRL1, MGLL | CHRNB2 80/4885SLC6A2 84/4885CHRNB4 57/4885 |
| US-20020019396-A1 | Pharmaceutically active morpholinol | ACHE, COMT, OPRL1 | CHRNB2 74/4885SLC6A2 67/4885CHRNB4 54/4885 |
| US-20030064988-A1 | Pharmaceutically active morpholinol | ACHE, COMT, OPRL1 | CHRNB2 74/4885SLC6A2 72/4885CHRNB4 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.